Form 4: Glaukos COO Joseph Gilliam Earns Performance-Based Stock Options
Statement of Changes in Beneficial Ownership
Glaukos Corporation's President and COO, Joseph E. Gilliam, has earned 7,316 performance-based stock options, reflecting the achievement of operational targets.
Summary
- Joseph E. Gilliam, President & COO of Glaukos Corporation (GKOS), acquired 7,316 stock options.
- These options are part of a larger grant from March 24, 2022, contingent on achieving pre-determined operational targets.
- The Compensation, Nominating & Governance Committee confirmed the achievement of these targets.
- The options have an exercise price of $55.18.
- The vesting schedule for these 7,316 options is 50% in March 2026 and the remaining 50% in December 2026.
- Following this transaction, Mr. Gilliam beneficially owns 65,013 derivative securities.
- The transaction was made pursuant to a Rule 10b5-1(c) plan.
Sentiment
Score: 7
Explanation: The filing indicates positive news regarding the company's operational performance, as evidenced by the achievement of targets leading to executive stock option vesting. This suggests good internal execution and management alignment.
Positives
- Achievement of pre-determined operational targets by Glaukos Corporation, leading to the vesting of performance-based stock options for the President & COO.
- The grant aligns management incentives with company performance.
Future Outlook
The filing indicates future vesting events for the acquired stock options, with 50% vesting in March 2026 and the remaining 50% in December 2026, contingent on continued employment or other terms of the grant.
Industry Context
This transaction reflects standard executive compensation practices within the medical technology or ophthalmology industry, where performance-based equity awards are used to incentivize leadership and align their interests with long-term company success. The achievement of operational targets suggests positive internal performance within Glaukos, which is a common driver for such awards.
Comparison to Industry Standards
- The use of performance-based stock options is a common practice in the medical device and biotechnology sectors, similar to compensation structures seen at companies like Alcon (ALC) or Bausch + Lomb (BLCO), aiming to link executive rewards directly to company operational achievements and shareholder value creation.
Stakeholder Impact
- Shareholders: Potential positive impact due to management's incentives being aligned with company performance and the achievement of operational targets.
- Employees: Reflects a company that is meeting its internal operational goals, which can be a positive indicator for overall company health and stability.
Next Steps
- 50% of the earned stock options will vest and become exercisable in March 2026.
- The remaining 50% of the earned stock options will vest and become exercisable in December 2026.
Key Dates
| Date | Description |
|---|---|
| 03/24/2022 | Original grant date of the stock option. |
| 12/11/2025 | Date of earliest transaction for the acquisition of stock options. |
| 12/15/2025 | Signature date of the reporting person's attorney-in-fact. |
| March 2026 | 50% of the reported stock options will vest and become exercisable. |
| December 2026 | The remaining 50% of the reported stock options will vest and become exercisable. |
| 03/24/2032 | Expiration date of the stock option. |
Keywords
Glaukos Corporation, GKOS, Joseph E Gilliam, Stock Options, Performance-Based Compensation, SEC Form 4, Insider Trading, Executive Compensation, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.